雷帕鸣用于治疗什么病

(sirolimus) is a non-nephrotoxic immunosuppressant that is mainly used clinically for patients aged 13 or above who have received kidney transplants to prevent organ rejection.

While sirolimus (i.e. rapamycin) is immunosuppressive, it has attracted clinical attention because of its non-nephrotoxicity, anti-tumor and ability to reduce cytomegalovirus infection. On the premise that the quality of the donor kidney is satisfactory, the immune risk is small, the primary kidney disease is not closely related to massive proteinuria, and patients who are not prone to delayed wound healing after surgery can consider using sirolimus in the early stage after kidney transplantation; when sirolimus is used in the early stage after kidney transplantation, appropriate antibody induction protocols should be used, and the drug concentration should be closely monitored.

When switching from calcineurin inhibitor drugs to sirolimus after kidney transplantation, the age of the donor, the time since the kidney transplant surgery, the patient's renal function at the time of switching, pathological tissue damage score and urinary protein level are all important factors that affect the switching effect. Delayed wound healing caused by the initial use of sirolimus after kidney transplantation can be effectively prevented through corresponding measures. Complications such as proteinuria and hyperlipidemia caused by sirolimus can be alleviated by the use of relevant drugs.

In a multicenter clinical study, 31 patients with chronic allograft nephropathy (suggesting chronic nephrotoxicity of calcineurin inhibitors, with or without nonspecific renal interstitial fibrosis or tubular atrophy) diagnosed by transplant kidney biopsy were treated with a treatment regimen that switched from calcineurin inhibitors to sirolimus, with an average follow-up of 21.6 months. 

The results showed that 1 year after switching (sirolimus tablets) treatment, the patient's renal function was significantly improved [cGFR: (40.8±2.36) mL/min vs. (55.7±3.6) mL/min; P < 0.000]. No kidney transplant loss and patient death were observed during follow-up. In this regard, patients can purchase and use this medicine with confidence.

Recommended hot articles: /newsDetail/72939.html